
Mesa Laboratories, Inc.
NASDAQ•MLAB
CEO: Mr. Gary M. Owens
Sector: Technology
Industry: Hardware, Equipment & Parts
Listing Date: 1984-02-29
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Contact Information
Market Cap
$447.42M
P/E (TTM)
-714.2
69.8
Dividend Yield
0.8%
52W High
$155.12
52W Low
$55.45
52W Range
Rank35Top 21.9%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q2 2026 Data
Revenue
$60.74M+5.02%
4-Quarter Trend
EPS
$0.45-28.57%
4-Quarter Trend
FCF
$7.13M+104.71%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Six Month Revenue Growth Total revenues reached $120.28M for six months, reflecting 3.7% growth versus comparable prior period.
Biopharma Segment Surge Biopharmaceutical Development revenue increased 17.3% for the quarter, primarily driven by higher sales of Peptides instruments.
Working Capital Improvement Working capital turned positive $49.1M from negative $(61.3)M after settling $97.5M principal convertible Notes.
Q3 Net Income Decline Net income for the quarter was $2.48M, a decrease of 27.8% compared to the prior year period.
Risk Factors
Gross Margin Compression Six months gross profit margin fell 1.0 point to 61.7%, negatively impacted by tariffs and foreign currency.
China Market Headwinds Clinical Genomics revenue declined 6.4% due to ongoing macroeconomic uncertainty and escalating trade tensions in China.
Operating Expense Increase Total operating expenses rose 4.5% for six months, driven by higher personnel costs and foreign currency translation.
Goodwill Impairment Risk Clinical Genomics and Peptides reporting units carry heightened risk of future impairment losses based on valuation assumptions.
Outlook
Cost Structure Optimization Initiated cost savings expected to reduce annualized costs by $3.2M, reinvesting $0.9M into Sterilization division.
Credit Facility Rate Reduction Amended Credit Facility reduced interest spread, resulting in estimated annual cost savings of approximately $0.6M.
Future Interest Expense Expect interest expense to increase in remainder of FY2026 due to higher rates on outstanding Credit Facility debt.
Equity Plan Expansion Shareholders approved increasing authorized shares for the 2021 Equity Incentive Plan by 496 shares to 1,156.
Peer Comparison
Revenue (TTM)
$15.09B
$3.07B
$299.28M
Gross Margin (Latest Quarter)
EGAN72.7%
PUBM62.6%
MLAB54.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| FEIM | $518.41M | 24.6 | 37.9% | 9.1% |
| VPG | $514.33M | 64.8 | 2.4% | 0.0% |
| MLAB | $447.42M | -714.2 | -0.4% | 42.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.1%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 3, 2026
EPS:$2.41
|Revenue:$63.23M
Reports
All Years
Form 10-Q - Q2 2026
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $60.74M+5.0%|EPS: $0.45-28.6%MissForm 10-Q - Q1 2026
Period End: Jun 30, 2025|Filed: Aug 5, 2025|Revenue: $59.54M+2.4%|EPS: $0.87+38.1%MissForm 10-K - FY 2025
Period End: Mar 31, 2025|Filed: May 28, 2025|Revenue: $240.98M+11.5%|EPS: $-0.36+99.2%MissForm 10-Q - Q3 2025
Period End: Dec 31, 2024|Filed: Feb 4, 2025|Revenue: $62.84M+17.5%|EPS: $-0.31-179.5%MissForm 10-Q - Q2 2025
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $57.83M+8.8%|EPS: $0.63-373.9%MissForm 10-Q - Q1 2025
Period End: Jun 30, 2024|Filed: Aug 5, 2024|Revenue: $58.17M+14.9%|EPS: $0.63-730.0%MissForm 10-K - FY 2024
Period End: Mar 31, 2024|Filed: Jun 28, 2024|Revenue: $216.19M-1.3%|EPS: $-47.20-27864.7%MissForm 10-Q - Q3 2024
Period End: Dec 31, 2023|Filed: Feb 5, 2024|Revenue: $53.47M-1.5%|EPS: $0.39+361.5%Miss